

Supplementary Information

(2*S*,4*S*)-4-*tert*-Butyl-2,5,5-triphenyl-oxazolidine (5a)

A solution of aminoalcohol **4a** (1.21 g, 4.50 mmol) and benzaldehyde (0.55 mL, 5.4 mmol) in CH₂Cl₂ (70 mL) was stirred at room temperature for 24h in Ar. Solvent was removed under a reduced pressure. The residue was purified by flash chromatography to afford the oxazolidine **5a** (1.58 g, 98%).

5a : colorless crystal (AcOEt). mp 149-152 °C. $[\alpha]_D^{24} = -59.55$ (c 2.25, CHCl₃). IR (KBr) cm⁻¹ : 3461. ¹H-NMR (CDCl₃) δ: 8.14 (s, (1/3)1H), 7.73-7.11 (m, 15H), 5.33 (s, (2/3)1H), 4.08 (s, (1/3)1H), 4.05 (s, (2/3)1H), 0.82 (s, (2/3)9H), 0.79 (s, (1/3)9H). ¹³C-NMR (CDCl₃) δ: 162.22, 149.24, 147.00, 144.94, 135.73, 130.68, 129.35, 128.45, 128.04, 127.91, 127.72, 127.19, 127.05, 126.47, 126.32, 126.27, 125.85, 125.80, 88.21, 83.06, 80.12, 75.54, 36.28, 33.71, 29.55, 28.47. *Anal.* Calcd for C₂₅H₂₇NO: C, 83.99; H, 7.61; N, 3.92. Found: C, 84.02; H, 7.84; N, 3.85. EI-MS *m/z* : 357 (M⁺) ; HRMS (EI) : calcd for C₂₅H₂₇NO (M⁺) 357.2093, found 357.2110.

(2*S*,4*S*)-4-*tert*-Butyl-2,5,5-triphenyl-oxazolidine trifluoroacetate (6a)

A solution of oxazolidine **5a** (578 mg, 1.62 mmol) and trifluoroacetic acid (0.12 mL, 1.62mmol) in CH₂Cl₂ (25 mL) was stirred at 0 °C for 1 min in Ar. Solvent was removed under a reduced pressure to give the oxazolidine salt **6a** in quantitative yield.

6a : colorless crystal (*n*-hexane). mp 70-72 °C. $[\alpha]_D^{20} = -102.88$ (c 2.08, CHCl₃). IR (KBr) cm⁻¹ : 3368, 1666. ¹H-NMR (CDCl₃) δ: 7.71 (brs, 2H), 7.58 (d, *J* = 7.3Hz, 2H), 7.47-7.29 (m, 11H), 5.56 (s, 1H), 4.68 (s, 1H), 0.85 (s, 9H). ¹³C-NMR (CDCl₃) δ: 143.25, 139.50, 130.67, 129.02, 128.99, 128.94, 128.92, 128.63, 128.28, 127.59, 127.57, 126.95, 126.92, 126.89, 89.82, 85.77, 71.72, 34.12, 27.65. *Anal.* Calcd for C₂₇H₂₈F₃NO₃: C, 68.78; H, 5.99; N, 2.97. Found: C, 68.79; H, 6.11; N, 2.86. FAB-MS *m/z* : 470 (M-H)⁻.

General procedure for the DA reaction of **1**, 2-dihydropyridine **9** with acrolein **10** using catalyst **6a**.

To a CH₃CN (1.0 mL) solution of catalyst **6a** (0.02 mmol), cold water (0.052 mL) and distilled acrolein **10** (0.013 mL, 0.20 mmol) was added at 0 °C and the solution was stirred. After 1 min, 1,2-dihydropyridine **9** (80mg, 0.040 mmol) was added and the solution was stirred at 0 °C for 24h. The reaction was quenched by water. The reaction mixture was diluted with water and extracted with diethyl ether. The combined organic extracts were washed with brine, dried over MgSO₄, and removed under reduced pressure to give crude DA adduct **11a**, which was used to the next reaction without purification.

To a stirred solution of product **11a** in ethanol (2.0 mL), NaBH₄ (4.0 mg, 0.10 mmol) was added and the mixture was stirred at room temperature for 1 h. Solvent was evaporated under a reduced pressure. The reaction mixture was diluted with water and extracted with AcOEt. The combined organic extracts were washed with brine, dried over MgSO₄, removed under reduced pressure to give a crude DA adduct **12a**. The residue was purified by flash chromatography (SiO₂, *n*-hexane : AcOEt = 1 : 1) to afford the DA adduct **12a** in quantitative yield. The enantiomeric excess (ee) was determined by HPLC [DAICEL Chiralcel AD-H, 0.5 mL/min, *n*-hexane : 2-propanol = 85 : 15, *t_r* (major) = 21.64 min, *t_r* (minor) = 23.09 min for **12a** (>99% ee), DAICEL Chiralcel AD-H, 0.5mL/min, *n*-hexane : 2-propanol = 85 : 15, *t_r* (minor) = 16.97 min, *t_r* (major) = 20.50 min for **12b**]. For the ee's of other catalysts: catalyst **6b** (**12a**: 97% ee), **8a** (**12a**: 27% ee, **12b**: 29% ee), **8b** (**12a**: 85% ee, **12b**: 39% ee), **6e** (**12a**: 39% ee, **12b**: 18% ee), **6f** (**12a**: 33% ee), **6g** (**12a**: 42% ee).


(1*S*,4*S*,7*S*)-7-Hydroxymethyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylic acid

phenyl ester (12a) : colorless crystal (*n*-hexane/AcOEt). mp 110-112 °C. [α]_D²¹ = 95.00 (c 1.00, CHCl₃). IR (KBr) cm⁻¹ : 3507, 1694, 1408. ¹H-NMR (CDCl₃) δ : 7.36-7.32 (m, 2H), 7.18 (t, *J* = 7.2Hz, 1H), 7.13-7.10 (m, 1H), 6.41 (t, *J* = 7.0Hz, 1H), 5.01 (brs, (4/9)1H), 4.93 (brs, (5/9)1H), 3.50-3.06 (m, 4H), 2.82 (brs, 1H), 2.47 (brs, 1H), 1.86 (ddt, *J* = 11.6, 8.7, 2.9Hz, 1H), 0.96-0.85 (m, 1H). ¹³C-NMR (CDCl₃) δ : 151.34, 135.15, 134.80, 130.41, 129.89, 129.14, 125.07, 121.74, 65.49, 47.83, 47.42, 47.08, 41.53, 30.68, 26.05. *Anal.* Calcd for

C₂₄H₂₅NO: C, 69.48; H, 6.61; N, 5.40. Found: C, 69.65; H, 6.69; N, 5.41. EI-MS *m/z* : 259 (M⁺) ; HRMS (EI) : calcd for C₁₅H₁₇NO₃ (M⁺) 259.1208, found 259.1202.

The absolute stereochemistry assignment of the new DA adducts **11a**, **16**, **20**, **21**


The absolute stereochemistry assignment of the new DA adducts **11a**, **16**, **20**, **21** was carried out as follows (Scheme 1, 2). Both **11a** and the known (7*R*)-**24**^{7c} were converted to the alcohol **12a** by the synthetic methodology as shown in Scheme 1. The compound **24** gave (7*R*)-(-)-**12a** and **11a** afforded the enantiomer (7*S*)-(+)-**12a** of (7*R*)-(-)-**12a**. On the other hands, the absolute stereochemistry of DA adduct **16** was determined by the conversation from 1-*tert*-butoxycarbonyl-**18a** to the known 1-benzyloxycarbonyl-**17a**.



Scheme 1 Determinations of the absolute stereochemistry of **11a**,**16**

To assign the structure of 1-phenoxycarbonyl-**20** by X-ray study, the compound was converted to bromolactone **25** (Scheme 2). Thus, the Kraus oxidation of **20** and the bromolactonization of the obtained carboxylic acid afforded the desired bromolactone **25**. On the other hands, the absolute stereochemistry of 1-benzyloxycarbonyl-**21** was decided by

converting to **26**. Thus, compound **22** for which the absolute stereochemistry was determined, was converted to alcohol **26**, by reduction of the olefin moiety in **22**. The similar reduction of alcohol **23** that was derived from **20**, followed by the exchange from the Cbz group to the phenoxycarbonyl group on nitrogen at 2-position, and then the reaction with K_2CO_3/H_2O afforded the alcohol **26**.



Scheme 2 Determinations of the absolute stereochemistry of **20,21**